アルツハイマー病のインタラクトーム,マクロ分子複合体,薬物発見の経路の採掘
Kalpana Panneerselvam1, Krishna Kumar Tiwari1, Luana Licata2
1European Bioinformatics Institute (EMBL-EBI), European Molecular Biology Laboratory, Hinxton, Cambridge, UK.
Proteomics
|August 26, 2025
まとめ
この研究はアルツハイマー病の変異を タンパク質の相互作用と 制御ネットワークにマッピングしています 発見により アルツハイマー病の治療に 障害が生じ 治療対象となる可能性が明らかになりました
科学分野:
- 神経科学
- 分子生物学
- 遺伝学
背景:
- アルツハイマー病 (AD) は進行性神経変性疾患で 認知症を引き起こし 治療法はない.
- アルツハイマー病の分子基盤を理解することは 効果的な治療法の開発に不可欠です
- 遺伝子変異を分子相互作用にマッピングすることで 病気の経路の洞察が得られます
研究 の 目的:
- アルツハイマー病に関連した突然変異がタンパク質の相互作用と制御ネットワークをどのように変化させるかを特定する.
- 変異特有の脳組織の 障害経路を明らかにする
- アミロイド前駆体タンパク質 (APP) のタンパク質インタラクタを分析することによって治療目標を探求する.
主な方法:
- ADデータセットの差分インタラクトーム解析
- 脳の関連組織における変異特有のタンパク質相互作用のマッピング.
- ミクロRNA (miRNA) 媒介による調節のリアクトーム濃縮分析と統合.
主要な成果:
- AD変異による一時的および安定的なタンパク質相互作用の変異を特定した.
- マクロ分子組成と混乱した経路の変異特有の障害を発見した.
- 主要なAD遺伝子に対するmiRNA媒介のポストトランスクリプション制御と,APPインタラクターベースの治療標的を特定した.
結論:
- 多層戦略はAD分子ネットワークを理解するための枠組みを提供します.
- このアプローチは,アルツハイマー病の精密な治療戦略の特定を容易にする.
- 遺伝子変異をインタラクトームにマッピングすることで ADの病原性についての理解が深まります
関連する概念動画
01:26Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
01:22Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
02:26Protein Networks
4.1K
An organism can have thousands of different proteins, and these proteins must cooperate to ensure the health of an organism. Proteins bind to other proteins and form complexes to carry out their functions. Many proteins interact with multiple other proteins creating a complex network of protein interactions.
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
These interactions can be represented through maps depicting protein-protein interaction networks, represented as nodes and edges. Nodes are circles that are representative of a protein,...
4.1K
01:26Drug Discovery: Overview
8.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.7K
02:04Protein-protein Interfaces
13.2K
Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
13.2K
03:03Amyloid Fibrils
9.9K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.9K